Shopping Cart (0)
My Account

 Shopping Cart
Conferences | Training Courses | Market Reports | Managed Events | Past Conferences | Update Me
SELECTBIO Conferences Sample Preparation and Analysis
Conferences  \  Circulating Biomarkers World Congress 2015  \  Sample Preparation and Analysis  \  Agenda  \  Doug Taylor
RegisterLogin

Doug Taylor's Biography


Doug Taylor, Chief Scientific Officer, Exosome Sciences Inc

Dr. Taylor discovered and pioneered the field of exosome biology and their role in intercellular communication and immune regulation. He previously has worked at the, Gynecology and Women's Health at the University of Louisville School of Medicine since 1992. Dr. Taylor published the initial article describing circulating tumor exosomes/microvesicles in 1979 (Anal. Biochem. 98:53-59, 1979). The research in his laboratory has primarily focused on the release and consequences of exosomes from gynecologic cancer and lung tumors. Over the past 30+ years, Dr. Taylor has pioneered the isolation and characterization of circulating tumor-derived exosomes. His work has focused on characterization of circulating exosomes released by tumor cells for their role in immune regulation and induction of a pro-inflammatory tumor microenvironment. Additionally, his work has demonstrated that the presence of specific circulating exosomal components have potential use as biomarkers for cancer patients.

Doug Taylor Image

Exosomes: From “Dust” to Multiplexed Diagnostic Biomarker

Monday, 23 March 2015 at 09:00

Add to Calendar ▼2015-03-23 09:00:002015-03-23 10:00:00Europe/LondonExosomes: From “Dust” to Multiplexed Diagnostic BiomarkerSELECTBIOenquiries@selectbiosciences.com

Exosomes are nano-sized vesicles released by all cell types and their protein and RNA cargo mirror the composition of their originating cells. In the case of cancer cells, the released exosomes exhibit proteins and RNA associated with the tumor and can be used as surrogates to define tumor type and stage and to predict therapeutic responses. While exosomes possess the FDA-defined features of ideal biomarkers and can be easily obtained and assessed, several obstacles have limited their clinical applications. The most critical barrier to their diagnostic application is the isolation of disease-specific exosomes and characterization their cargo. Emerging technologies will be discussed by the isolation of exosomes, associated specifically with cancers, allowing their use in diagnosis, patient stratification for therapy, monitoring therapeutic responses in real time and early identification of recurrence. These approaches target the unique properties and compositions of specific vesicle populations. The isolation of enriched pathology-specific vesicles enhances the signal to noise ratio and allows the identification of markers directly derived from the specific cell types. By correlating these circulating markers with the molecular characteristics and real-time clinical parameters, the use of circulating vesicles represents the ideal, multiplexed marker platform for clinical management.

Add to Calendar ▼2015-03-23 00:00:002015-03-24 00:00:00Europe/LondonSample Preparation and AnalysisSELECTBIOenquiries@selectbiosciences.com


Corporate Sponsors
Related Conferences
Organoids and Spheroids Europe 2024
Location: Rotterdam, The Netherlands
Date: 24/06/2024 - 25/06/2024


Organoids, Spheroids & Organs-on-Chips 2024
Location: Laguna Hills, California
Date: 18/11/2024 - 20/11/2024


Lab-on-a-Chip, Microfluidics, & Organ-on-a-Chip Asia 2024
Location: Tokyo, Japan
Date: 07/11/2024 - 08/11/2024